Abstract
Background
Malignant glioma carries a poor prognosis despite current therapeutic modalities. Standard of care therapy consists of surgical resection, fractionated radiotherapy concurrently administered with temozolomide (TMZ), a DNA-alkylating chemotherapeutic agent, followed by adjuvant TMZ. O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair enzyme, removes alkylated lesions from tumor DNA, thereby promoting chemoresistance. MGMT promoter methylation status predicts responsiveness to TMZ; patients harboring unmethylated MGMT (~60% of glioblastoma) have a poorer prognosis with limited treatment benefits from TMZ.
Methods
Via lentiviral-mediated delivery into LN18 glioma cells, we employed deactivated Cas9-CRISPR technology to target the MGMT promoter and enhancer regions for methylation, as mediated by the catalytic domain of the methylation enzyme DNMT3A. Methylation patterns were examined at a clonal level in regions containing Differentially Methylation Regions (DMR1, DMR2) and the Methylation Specific PCR (MSP) region used for clinical assessment of MGMT methylation status. Correlative studies of genomic and transcriptomic effects of dCas9/CRISPR-based methylation were performed via Illumina 850K methylation array platform and bulk RNA-Seq analysis.
Results
We used the dCas9/DNMT3A catalytic domain to achieve targeted MGMT methylation at specific CpG clusters in the vicinity of promoter, enhancer, DMRs and MSP regions. Consequently, we observed MGMT downregulation and enhanced glioma chemosensitivity in survival assays in vitro, with minimal off-target effects.
Conclusion
dCas9/CRISPR is a viable method of epigenetic editing, using the DNMT3A catalytic domain. This study provides initial proof-of-principle for CRISPR technology applications in malignant glioma, laying groundwork for subsequent translational studies, with implications for future epigenetic editing-based clinical applications.
Similar content being viewed by others
Introduction
For malignant glioma, specifically glioblastoma (GBM, IDH wild-type), a central aspect of clinical decision-making and prognosis is the de novo methylation status of the promoter of O-6-methylguanine-DNA methyltransferase (MGMT) [1,2,3,4,5,6,7,8], routinely assayed during neuropathologic diagnosis. MGMT repairs the toxic DNA lesion O6-methylguanine induced by alkylating chemotherapeutic agents, such as temozolomide (TMZ), thereby undermining the mechanism of action of TMZ, leading to chemoresistance. As the only FDA-approved drug with relative improvement in survival, TMZ comprises the current standard of care chemotherapy in combination with fractionated radiation [6, 7]. Approximately 40% of GBM patients harbor methylated MGMT, silencing expression in tumor cells, enhancing chemosensitivity and survival (progression-free survival (PFS) = 10.3 months, overall survival (OS) = 21.7 months) [2]. By contrast, the preponderance of GBM patients (60%) harbor unmethylated MGMT and exhibit chemoresistance to TMZ [1,2,3, 5,6,7,8,9,10,11,12], markedly reducing survival (PFS = 5.3 months, OS = 12.7 months) [2].
To date, multiple attempts to combat TMZ chemoresistance, via direct inhibition or cellular depletion, have yielded no significant clinical improvements. A Phase II clinical trial using the direct MGMT inhibitor O-6-benzylguanine showed limited benefits but lacked clinical feasibility due to severe dose-limiting toxicities (including off-target bone marrow suppression) [13, 14]. A Phase III trial implemented dose-dense TMZ, aiming to deplete MGMT in tumor cells, but failed to improve TMZ sensitivity [15]. Given these adverse findings, we employed an alternative, CRISPR-based mechanism to target MGMT, consisting of a chimeric fusion of deactivated Cas9 (dCas9, lacking endonuclease activity) with an epigenetic editor, DNA methyltransferase 3A catalytic domain (DNMT3A-CD); this fusion protein is hereby collectively abbreviated as “d3A”. This system enabled targeted methylation of a subset of existing CpG sites within the MGMT gene with the goal of decreasing MGMT expression and increasing sensitivity to TMZ, without the need for cleavage of the target gene sequence [16, 17]. This approach has multiple advantages in comparison to other gene silencing techniques: (1) Specificity, due to single guide RNA (sgRNA) interactions with dCas9, facilitating target gene recognition; and (2) reversibility and relative safety, due to preservation of the underlying target DNA sequence, resulting from deactivation of Cas9 endonuclease activity (avoiding permanent cleavage of gene sequences) and due to modification at the epigenetic level only (methylation). Furthermore, we used multiple sgRNAs to methylate a wider range of target sequences, encompassing the promoter and enhancer region, thereby enhancing effects on MGMT transcription. Our target regions also included: (1) Differentially Methylated Region 2 (DMR2), most highly associated with MGMT mRNA suppression [18]; and (2) Methylation-Specific Polymerase Chain Reaction (MSP) region, conventionally used clinically to determine MGMT methylation status, located within DMR2 [2, 19].
We hypothesized that CRISPR-mediated methylation of the MGMT promoter region may serve as a therapeutic strategy to enhance chemosensitivity in malignant glioma by silencing MGMT expression. Here we demonstrated that d3A/CRISPR-directed methylation, encompassing portions of the promoter, enhancer, DMR and MSP regions, successfully downregulated MGMT expression, significantly improved TMZ chemosensitivity via in vitro survival assays, and yielded minimal off-target effects, as per genome-wide and transcriptome-wide correlative analyses (Illumina EPIC 850K methylation array and bulk RNA-Seq).
Methods
Cell culture and treatments
LN18 cells (ATCC, Cat#CRL-2610) were grown in standard conditions (DMEM cell culture medium, 10% fetal bovine serum and penicillin/streptomycin). TMZ (Santa Cruz Biotechnology Cat #85622-93-1) was dissolved in DMSO.
Plasmids and lentiviral transduction
dCas9-DNMT3A catalytic domain plasmids were constructed by Pflueger et al. (Addgene, Cat#100936). Cas9 plasmids were obtained from Addgene (Cat#108100). We designed sgRNA sequences using the Broad Institute Genetic Perturbation Platform. Refer to Table S1 (Supplementary Information, Online Resource 1) for input sequence and resultant sgRNA sequences.
All sgRNA constructs were mounted on lentivirus-compatible plasmids (Vector Builder). Plasmids were packaged with pMD2.G VSV-G envelope plasmid (Addgene, Cat#12259), pCMVR8.74 packaging plasmid (Addgene, Cat#22036), and X-tremeGENE HP DNA Transfection Reagent (MilliporeSigma, Cat#XTGHP-RO) in HEK293T cells cultured in DMEM; virus was harvested after 48 h. LN18 cells were transduced with lentivirus-containing media and culture media in a 1:3 ratio including polybrene (1.0 μg/mL) for 48 h, with 24-h recovery in DMEM, prior to antibiotic selection.
Bisulfite sequencing
DNA was isolated using DNEasy Blood & Tissue Kit (Qiagen, Catalog #69506). Bisulfite conversion was accomplished using EZ DNA Methylation-Gold (Zymo Research, Catalog #D5005) per kit protocol. Nested PCR primers were used as follows:
-
Region 1: First PCR primer pair F4/R4; second PCR pair F5/R4.
-
Region 2: First PCR primer pair F1/R1; second PCR pair F1/SeqR.
Refer to Table S1. Sequencing reactions were performed using BigDye Terminator v3.1 Cycle Sequencing Kit (ThermoFisher, Cat#433750) with sequencing primers (R4 primer = Region 1; SeqR primer = Region 2); samples were purified by PCR Clean-Up Performa Spin Columns (EdgeBio Cat#13266) and submitted for Sanger sequencing analysis (Laragen, Culver City, CA).
TA cloning
Sodium bisulfite-treated genomic DNA underwent nested PCR as above, for either Region 1 or 2. Resultant amplicons (second PCR products) were ligated with plasmid vector using the TA cloning kit (New England BioLabs, Cat#E1203S), used to transform DH5α competent E. coli cells (Invitrogen, Cat#18258012) by standard methods; clonal plasmids were isolated by PureLink™ HiPure Plasmid Miniprep kit (Invitrogen, Cat#K210003). DNA plasmid clones were sequenced per standard sequencing protocols as above.
RT-qPCR
RT was performed using SuperScript™ II Reverse Transcriptase (Invitrogen, Cat#REF100004925), followed by qPCR using standard protocols, with Roche FastStart Universal SybrGreen Master (Rox) (Sigma Aldrich, Cat#4913850001); annealing temperature: 55 °C; cycle: 30 (see Table S1 for primer sequences).
Methylation-specific PCR
Refer to previous publication for methods [19].
Immunoblotting
Western blot was performed by standard protocols using primary antibodies: anti-HA, rabbit, (1:1000, Sigma, Cat#H6908-100mL); anti-MGMT, mouse (1:1000, ThermoFisher, Cat#35-7000); GAPDH, mouse (1:2000, Proteintech Cat#60004-I-Ig) (see Online Resource 1 (Supplementary Information) for further details).
Cell survival assays
MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assays were performed using standard protocols. Briefly, a uniform number of cells (2300 or 4600 per plate) were cultured in 24-well plates for 5 days with TMZ (100 μM or 250 μM) or DMSO control treatment, exposed to pre-mixed MTT solution (0.5 mg/mL in culture media), and incubated at 37 °C for 1 h. Formazan product was extracted by cell lysis with DMSO (300 μL) and measured (560 nm absorbance with background subtraction of 660 nm). Clonogenic assays were conducted as previously described. Cells (250 or 350 per well) were seeded in 60-mm plates. After overnight incubation, TMZ/DMSO was added and replaced after 6 days. Following 12 days of total treatment, cells were washed in phosphate-buffered saline (PBS), fixed in 100% methanol, and stained with 0.5% crystal violet/25% methanol solution.
Statistical methods for MTT and clonogenic assays
Data were analyzed in Prism 9 via a student’s t-test or analysis of variance (ANOVA) where appropriate, and ANOVA post hoc analyses were performed using Tukey’s HSD test for multiple comparisons.
Differential methylation analysis and transcriptomic analysis
Genome-wide methylation and transcription profiling was achieved via the Illumina platform EPIC 850K methylation array. Briefly, genomic data (IDAT files) were imported into R [23] and processed via the minfi package for the generation of methylation M-values [24]. Custom scripts were written to determine variance (standard deviation) for each probe for unsupervised hierarchical clustering, while supervised hierarchical clustering was achieved by fitting the data to a linear model and evaluating it via empirical Bayes for differential methylation [25]. Expression (RNA transcription) was determined by aligning bulk RNA-Seq data to the genome via minimap2 and counting genes via HTSeq, which were then analyzed for differential expression using DESeq2 [26]. Theoretical sgRNA “hits” were determined using the Off-Spotter platform [27] (see Online Resource 1 (Supplementary Information) for further details).
Results
Selection of unmethylated MGMT cellular background, epigenetic editor, sgRNA construct design, and expression verification
After screening multiple glioma cell lines with MSP, western blot analysis and bisulfite sequencing (BiSEQ), we selected LN18 human glioma cells, given the unmethylated MGMT status within target regions of interest and high levels of de novo MGMT expression (Fig. S1). LN18 exhibits high TMZ EC50 values (400 μM) amongst glioma cell lines with chemoresistance reported over time [28]. For the effector enzyme, we selected the de novo methylator DNMT3A catalytic domain fused to dCas9 via a flexible linker plus HA tag [17], comprising a smaller plasmid construct more amenable to lentiviral delivery methods (Fig. 1a).
Given reported enhanced efficiency of d3A-mediated methylation using multiple sgRNAs broadening target regions [16, 17, 29,30,31,32], we designed four sgRNAs with specific homology to MGMT regions encompassing promoter, enhancer and exon 1 regions, within a GFP-tagged lentiviral plasmid (Fig. 1a, b). As a negative control, we established LN18 cells expressing d3A plus scRNA (scrambled sgRNA), bearing no exact sequence homology to any mammalian genomic regions (see Online Resource 1). We verified expression of HA-tagged d3A via western blot analysis of sgRNA-transduced cells and scRNA-transduced cells, relative to baseline native LN18 cells (Fig. 1c). Fluorescent microscopy confirmed sgRNA and scRNA expression (Fig. 1d), showing efficient lentiviral transduction efficiency (over 90% cells exhibiting GFP positivity).
BiSEQ confirms targeted MGMT methylation via dCas9/CRISPR system, suggesting methylation hotspot locations and possible minimum radius of methylation
Using BiSEQ, the gold standard for methylation status confirmation of individual CpG sites, we analyzed the following targets separately using TA cloning methods: (1) “Region 1,” encompassing sgRNA4, core/minimal promoter, and promoter regions; (2) “Region 2,” comprised of exon 1, intron 1 and enhancer in proximity to sgRNA1, 2, and 3 (Figs. 1b, 2a). Due to aforementioned key components which influence gene transcription, we selected these target regions, which also included Differentially Methylated Regions (DMR1 and DMR2) and the MSP region [18, 19]. Representative chromatograms are shown (Fig. 2b), comparing scRNA vs. sgRNA clones; blue arrows indicate methylated CpG sites (retained cytosines at CpG sites, “CG”) vs. unmethylated CpG sites (converted to thymine, “TG”).
The “composite” row of the schematic (Fig. 2a) illustrates relative frequency of methylated CpG sites; red shading intensity indicates methylation frequency amongst the clones analyzed here. Amongst Region 1 clones, there is apparent asymmetry with respect to methylation occurrence: The preponderance of methylated sites were located in the 5′ upstream region relative to sgRNA4, at CpG 22–38 (DMR1 and promoter region) but minimally noted in the partially overlapping region with the core promoter (CpG 50 and downstream to end of Region 1), which is downstream from sgRNA4. For Region 2, which encompassed sgRNA3, sgRNA1, and sgRNA2 target sequences, methylated CpG sites clustered toward the center of the amplicon, upstream of sgRNA2, within DMR2 and MSP regions, with greatest density and frequency at CpG 77, 81–89. Within Region 1, methylation appears to extend to a 20-bp radius upstream from sgRNA4, to the upstream 5′ limit of the amplicon (CpG 22). It is unknown whether methylation extends further upstream beyond CpG 22, as we did not assay this region here. Given close proximities of multiple sgRNA target sequences within Region 2 (sgRNA 1, 2, 3), methylation radius cannot be reliably ascertained in Region 2.
CRISPR-based MGMT methylation is sufficient to reduce MGMT expression and enhance chemosensitivity
Using polyclonal populations of cell lines stably transduced with MGMT-specific sgRNAs (sgRNA) vs. scrambled sgRNA (scRNA), RT-qPCR was performed, revealing significant downregulation in MGMT mRNA expression (p < 0.001, Fig. 3a). Gel electrophoresis of MGMT PCR end products is also shown, with Actin B (ACTB) as the internal control (Fig. 3b). Protein lysates from the same cell lines were analyzed by western blot, revealing marked downregulation of MGMT protein expression in the context of CRISPR-based methylation (Fig. 3c).
We investigated whether CRISPR-mediated epigenetic conversion was sufficient to enhance TMZ chemosensitivity, using MTT and clonogenic survival assays. We compared survival in sgRNA vs. scRNA cells treated with DMSO (vehicle), 25 μM TMZ, or 100 μM TMZ using two-factor ANOVA. ANOVA analysis of MTT results revealed main effects of sgRNA treatment (F(1, 74) = 213.3, p < 0.0001), TMZ treatment (F(2,74) = 93.52, p < 0.0001), as well as an sgRNA/TMZ interaction (F(2, 74) = 86.92, p < 0.0001) (Fig. 4a). Clonogenic assays yielded analogous results between low-dose TMZ-treated cells and DMSO controls (ANOVA, TMZ treatment F(2, 56) = 186.2, p < 0.0001) (Fig. 4c). A post hoc Tukey test (p < 0.0001) showed enhanced sensitization to TMZ occurred at concentrations as low as 25 μM (Fig. 4c).
To compare direct Cas9 endonuclease disruption of MGMT vs. deactivated Cas9-based methylation effects, we generated Cas9-mediated MGMT knockout LN18 cells (transduced with sgRNA constructs 1 and 2). Extent of chemosensitization was comparable between Cas9-mediated knockout lines vs. d3A-mediated methylation when evaluated via MTT (ANOVA, F(1, 8) = 2.843, p = 0.1303), but a difference was observed via clonogenic assays (F(1, 8) = 9.587, p = 0.0147). Both assays, however, demonstrate clear TMZ sensitivity due to d3A-mediated methylation (Fig. 4b, d). Essentially no TMZ sensitivity was observed in LN18 d3A cells expressing the scRNA negative control construct. This indicates that epigenetic conversion is a sufficient, viable alternative strategy to enhance chemotherapeutic response, obviating the need for permanent target gene cleavage.
Validation of dCas9/CRISPR-based target specificity: Genome-wide vs. transcriptome-wide correlative analysis
To determine on-target and off-target effects of dCas9/CRISPR-based methylation, we performed genome-wide analysis of LN18 cells expressing the d3A/sgRNA system vs. d3A/scRNA negative control using the Illumina EPIC 850K methylation array, followed by transcriptomic analysis via bulk RNA-Seq (pipeline shown in Fig. 5a). Probes with the highest M-value variances (2.5 SDs greater than the average M-value SD) were used to generate an unsupervised hierarchical heatmap (total 21,278 probes), plotted by Illumina probe and LN18 cell type (sgRNA vs. scRNA). This necessary step demonstrated that samples of concordant cell type segregated accordingly (scRNA samples clustered together and sgRNA samples likewise clustered together) (Fig. 5b). Supervised hierarchical clustering was performed sequentially (details in Methods and Supplementary Information/Online Resource 1), identifying genes with the greatest difference in methylation state following d3A/CRISPR-mediated methylation (baseline unmethylated in scRNA cells but methylated in sgRNA cells). A total of 333 unique genes were identified, including three probes within the MGMT gene (Fig. 5f): cg12434587 (open star) and cg01341123 (half-closed star), both in proximity to sgRNA4, and cg12981137 (closed star), in proximity to sgRNA1, 2, and 3 loci (Fig. 1b), providing additional confirmation of on-target effects.
To elucidate effects on transcriptomic changes, we performed Bulk RNA-Seq analysis on the same LN18 glioma cell lines (refer to Methods and Online Resource 1). The 333 unique genes identified by secondary supervised hierarchical clustering were cross-referenced with bulk RNA-Seq differential expression data, yielding ten total gene hits, including MGMT as the top probe hit, serving as on-target confirmation (Fig. 5g). Subsequently, we used the Off-Spotter program [27] to blast sgRNA 1, 2, 3, 4 sequences for off-target prediction hits. Of the ten genes that emerged from the three-part analysis, namely, (1) DNA differential methylation, (2) RNA differential expression, (3) Off-spotter intersection, MGMT emerged as the singular gene hit fitting all criteria; the only hits emerging were MGMT probes (refer to Online Resource 3, Table S3). The nine additional “off target” gene probe hits had Off-Spotter hits hundreds of thousands of bases away from the probe that emerged from analysis. One exception was FAM84A, but RNA expression was incongruent with DNA methylation (i.e., increased DNA methylation but with increased RNA transcription). From basic interrogation of Off-Spotter hits within 1000 bases of the Illumina probe, none of the results fit the aforementioned DNA/RNA criteria. Our findings suggest CRISPR-based methylation using d3A appears specific for MGMT with minimal off-target effects.
We also performed gene ontology analysis, using Metascape, on the differentially expressed genes following CRISPR-mediated MGMT methylation, from data obtained via bulk RNA-Seq. Two separate analyses were performed: One for downregulated genes (defined as DESeq2 log2 fold change less than zero) and a separate analysis for upregulated genes (defined as DESeq2 log2 fold change greater than zero). Results are shown in Table S3. Among the top categories of downregulated genes were cytokine/inflammatory signaling pathways such as NF-kB survival signaling, interleukin-10 signaling, lipopolysaccharide response, as well as cell migration positive regulatory pathways. Among the top categories of upregulated genes included adhesion, migration, chemotaxis, and extracellular matrix organization pathways. Whether these pathways exhibit any functional biologic consequences as a result of MGMT methylation remains to be determined.
Discussion
The current study provides proof-of-principle evidence that the d3A/CRISPR methylation system is sufficient for targeted methylation at a high frequency and density within the MGMT promoter and enhancer regions (including DMR1, DMR2 and MSP). This methylation is likewise sufficient for MGMT downregulation and chemosensitization, reflected by significant reductions of tumor cell survival in vitro. Correlative analyses of genomic and transcriptomic changes provided initial validation of target specificity, with no definitive off-target effects identified. Supervised hierarchical clustering of Illumina methylation data identified three differentially methylated probes within MGMT: Two probes (cg12434587 and cg12981137) were congruent with prior reports in GBM patient samples using the MGMT-STP27 logistic regression model [33], localized to the promoter, correlating with patient outcomes; the third probe (cg01341123), upstream to Region 1, has not been previously reported as a survival correlate. Future studies can confirm epigenetic and clinical significance of this upstream region via clonal analysis. The regression model noted CpG sites in proximity to TSS and on the far 5′ and 3′ ends of the CpG island did not correlate with OS [33]. We examined the TSS region and far 3′ end, outside the regions of high methylation frequency/density, suggesting methylation in these areas is not required for MGMT suppression and chemosensitization.
Given proximity of multiple sgRNAs in Region 2, it is unknown whether they equally or hierarchically influence methylation patterns. Future studies can elucidate effects of a singular sgRNA on CpG cluster methylation, i.e. whether an upstream methylation propensity truly exists, relative to sgRNA target locus. The poorly defined methylation radius in Region 2 can be clarified with this method. The d3A/CRISPR system can be conveniently harnessed to probe relative clinical significance of CpG site methylation throughout the CpG island, effects on gene transcription, and elucidate possible methylation interdependence between CpG sites. For future clinical application, the minimum complement of sgRNA payload required to achieve the current methylation patterns should be determined.
Furthermore, as regards interpretation of the current hierarchical clustering methylation heatmaps, three main concepts are important to consider: (1) methylated probes do not necessarily correspond to transcriptional changes; (2) indirect effects on methylation cannot be disregarded; (3) multiple probes can often represent a single gene. There are numerous Illumina probes found across a given CpG island of a single gene, by virtue of CpG island length. Each probe, when methylated, may not translate directly into a transcriptional change, as the impact of methylation depends upon probe location, relative to the promoter/enhancer region(s) of a given gene. Future studies are needed to address these relative proximities. In addition, we cannot rule out indirect effects on methylation and transcription. MGMT is a critical DNA repair enzyme; therefore, silencing its activity may disrupt methylation indirectly. For example, in the instance that a DNA demethylase gene is not repaired in the absence of MGMT, resulting in failure of demethylation in a downstream target gene, this would be considered an “off-target” effect unrelated to the sgRNA/dCas9-DNMT3A system. It is currently unknown what potential gene networks might be affected by the dCas9-DNMT3A-CD/MGMT system through other mechanisms. However, despite this, our current methylation “off-target hits” did not correspond to a functional change in mRNA transcription from the DESeq2 intersection analysis, and therefore may not have a clinical impact. Further study may be warranted to ensure this is the case. Finally, although at first glance, the methylation hits may appear as a myriad, it is important to note that a single gene can be represented by multiple probes (rows) on the heatmap. For instance, MGMT is represented by three rows (denoted by stars in Fig. 5f); the heatmap shown here appears to be many genes, but in reality, there are few, due to this phenomenon. The vast majority of genes analyzed through the Illumina pipeline were unaltered. Likewise, as regards interpretation of gene ontology analysis of upregulated vs. downregulated pathways in the context of CRISPR-mediated MGMT methylation, it is unclear whether the aforementioned cytokine/inflammatory and chemotaxis phenomena are truly altered in this context; further studies are needed to ascertain whether these pathways exhibit any biologic effects or are simply artifactual and indirect.
During final submission preparations of the current manuscript, another manuscript was recently published [34] in which a very similar CRISPR-based approach was successfully used to sensitive LN18 human GBM cells to TMZ. As in the current study, a deactivated Cas9 system was used, in fusion with a DNMT3A-based methylation enzyme system, although with some variations in methodology. Our results support and extend these findings, reinforcing the resultant chemosensitization observed after targeted CRISPR-based methylation, in addition to specific CpG site methylation and potential off-target effect analysis at a genome-wide level.
We are optimizing conditions for CRISPR-based methylation in patient-derived gliomasphere cell lines and ex vivo xenograft studies. LN18 glioma cells provided an appropriate genetic landscape for current proof-of-principle studies, but our confirmed lack of intracranial tumor engraftment in vivo (data not shown), corroborated by previous attempts by others [35] necessitates using alternative cellular backgrounds.
Future translational studies of CRISPR-based methylation should address the following anticipated challenges: Selection/optimization of delivery vehicle (e.g., viral vectors vs. nanoparticles, and systemic vs. intratumoral delivery); payload definition (e.g., ribonucleoprotein complex of dCas9 and target sgRNAs); physiologic obstacles impacting optimal delivery (blood brain barrier impedance/penetration, solid tumor context preventing uniform penetration, and engineering mechanisms to achieve specificity for target cells). In summary, the current approach provides the initial foundation for subsequent preclinical and translational endeavors using modified dCas9/CRISPR-based epigenetic editing in the malignant glioma context, achieving chemosensitivity within a theoretically reasonable safety profile.
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028
Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. https://doi.org/10.1056/NEJMoa043331
Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199. https://doi.org/10.1200/JCO.2007.11.5964
Ostrom QT, Gittleman H, Liao P et al (2017) CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88. https://doi.org/10.1093/neuonc/nox158
Reifenberger G, Hentschel B, Felsberg J et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131:1342–1350. https://doi.org/10.1002/ijc.27385
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136. https://doi.org/10.1200/JCO.2007.11.8554
Wick W, Meisner C, Hentschel B et al (2013) Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81:1515–1522. https://doi.org/10.1212/WNL.0b013e3182a95680
Brandes AA, Franceschi E, Tosoni A et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518. https://doi.org/10.1002/cncr.24406
Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926. https://doi.org/10.1016/S1470-2045(12)70265-6
Rivera AL, Pelloski CE, Gilbert MR et al (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12:116–121. https://doi.org/10.1093/neuonc/nop020
Wiestler B, Claus R, Hartlieb SA et al (2013) Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol 15:1017–1026. https://doi.org/10.1093/neuonc/not043
Quinn JA, Jiang SX, Reardon DA et al (2009) Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol 11:556–560. https://doi.org/10.1215/15228517-2009-007
Schilsky RL, Dolan ME, Bertucci D et al (2000) Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 6:3025–3031
Gilbert MR, Wang M, Aldape KD et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. JCO 31:4085–4091. https://doi.org/10.1200/JCO.2013.49.6968
Liu XS, Wu H, Ji X et al (2016) Editing DNA methylation in the mammalian genome. Cell 167:233-247.e17. https://doi.org/10.1016/j.cell.2016.08.056
Pflueger C, Tan D, Swain T et al (2018) A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs. Genome Res 28:1193–1206. https://doi.org/10.1101/gr.233049.117
Malley DS, Hamoudi RA, Kocialkowski S et al (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121:651–661. https://doi.org/10.1007/s00401-011-0803-5
Lalezari S, Chou AP, Tran A et al (2013) Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol 15:370–381. https://doi.org/10.1093/neuonc/nos308
Franken NAP, Rodermond HM, Stap J et al (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319. https://doi.org/10.1038/nprot.2006.339
Hermisson M, Klumpp A, Wick W et al (2006) O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96:766–776. https://doi.org/10.1111/j.1471-4159.2005.03583.x
Remington M, Chtchetinin J, Ancheta K et al (2009) The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. Neuro Oncol 11:22–32. https://doi.org/10.1215/15228517-2008-080
R Core Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
Aryee MJ, Jaffe AE, Corrada-Bravo H et al (2014) Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30:1363–1369. https://doi.org/10.1093/bioinformatics/btu049
Ritchie ME, Phipson B, Wu D et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. https://doi.org/10.1093/nar/gkv007
Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https://doi.org/10.1186/s13059-014-0550-8
Pliatsika V, Rigoutsos I (2015) “Off-Spotter”: very fast and exhaustive enumeration of genomic lookalikes for designing CRISPR/Cas guide RNAs. Biol Direct 10:4. https://doi.org/10.1186/s13062-015-0035-z
Happold C, Roth P, Wick W et al (2012) Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem 122:444–455. https://doi.org/10.1111/j.1471-4159.2012.07781.x
Amabile A, Migliara A, Capasso P et al (2016) Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing. Cell 167:219-232.e14. https://doi.org/10.1016/j.cell.2016.09.006
McDonald JI, Celik H, Rois LE et al (2016) Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation. Biol Open 5:866–874. https://doi.org/10.1242/bio.019067
Stepper P, Kungulovski G, Jurkowska RZ et al (2017) Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase. Nucleic Acids Res 45:1703–1713. https://doi.org/10.1093/nar/gkw1112
Vojta A, Dobrinić P, Tadić V et al (2016) Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res 44:5615–5628. https://doi.org/10.1093/nar/gkw159
Bady P, Sciuscio D, Diserens A-C et al (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124:547–560. https://doi.org/10.1007/s00401-012-1016-2
Han X, Abdallah MOE, Breuer P et al (2023) Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma. Neoplasia 44:100929. https://doi.org/10.1016/j.neo.2023.100929
Takashima H, Tsuji AB, Saga T et al (2017) Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model. Sci Rep 7:12341. https://doi.org/10.1038/s41598-017-12563-5
Funding
SZR was funded by the UCLA Tumor Biology Postdoctoral Training Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award #T32 CA009056) and the UCLA JCCC Postdoctoral Research Award (2021FP04). STP was funded by the National Cancer Institute Ruth L. Kirschstein Research Service Award (#F30CA247525-01A1), the UCLA Tumor Biology Predoctoral Training Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award #T32 CA009056), and the UCLA-Caltech Medical Scientist Training Program (NIGMS T32 GM008042). AL was funded by the Department of Defense Award (CA190604), the BCured Foundation Grant (20199389), and the UCLA SPORE in Brain Cancer (NCI P50 CA211015).
Author information
Authors and Affiliations
Contributions
SZR performed portions of western blot experiments (Fig. 1c), portions of DNA BiSEQ and associated chromatograms (Fig. S1), all MTT and clonogenic survival assays (Fig. 4), performed DNA/RNA extractions from LN18 glioma cells used for Figs. 2, 4, and 5, thereby furnishing all bisulfite-converted DNA for subsequent TA cloning, Illumina EPIC 850K methylation array analysis and bulk RNA-Seq data. She also composed the Title, Abstract, Introduction, Results and Discussion section text, the preponderance of the Methods and Supplementary Methods, all figure legends (except for those pertaining to Illumina methylation-based analysis), and aided TJP in design of schematic figures. She compiled the initial manuscript, revised manuscript, and subsequently edited and reviewed the final manuscript. TL performed initial experiments to establish the working system of dCas9/DNMT3A-CD in glioma cells, designing all associated primers and sgRNAs employed in this study, performing preliminary proof-of-principle initial experiments (data not shown), generating Figs. 1d, 2b, c, 3, S1a, and S1b (immunocytochemistry images, RT-qPCR, MGMT western blots, TA cloning, methylation-specific PCR), with intellectual guidance of this study throughout. He also edited and reviewed the manuscript. STP generated the LN18 glioma cells for this manuscript via sequential lentiviral-mediated transduction with the dCas9/DNMT3A catalytic domain fusion protein construct and sgRNA constructs (used in Fig. 1). He composed parts of the Methods section, while editing and reviewing the manuscript. TJP generated all data related to Illumina EPIC 850K methylation array-based assessments of on-target effects and off-target effects, RNA-Seq analysis, and synthesized the final R scripts required for the current analyses (Fig. 5, Table S2, S3). He performed ANOVA analyses of MTT and clonogenic assays. He generated the graphics, organization and legends for the schematic diagrams (Figs. 1a, b, 2a, S2). He also composed the Methods, Results, and all figure legends specifically pertaining to methylation array and bulk RNA-Seq data analysis, ANOVA analyses, and Gene Ontology analysis. He performed the Gene Ontology analysis (Fig. S3) and intersection of Off-Spotter, Illumina, and DESeq2 data (Table S3). He generated the graphics and organization for Figs. 1 and S2 with guidance from TL and SZR. He also edited and reviewed the manuscript. BSCE collaborated in performing MTT and clonogenic survival assays with SZR; he also assisted in all associated statistical analyses for these data, in collaboration with TJP. He also edited and reviewed the manuscript. BMK provided the initial analyses for the Illumina EPIC 850K methylation array data and initial synthesis of R scripts for first-pass analysis, providing the initial groundwork for TJP’s subsequent expansion of the Illumina data analysis. AL, as Principal Investigator, furnished all funding and facilities related to the completion of this study, with intellectual guidance of this study throughout. He also edited and reviewed the manuscript. LML, PLN, and TFC assisted in editing and reviewing the scientific content of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
SZR, TL, STP, and AL have a U.S. Provisional Patent Application No. 63/429348 entitled TARGETED EPIGENETIC EDITING AS NOVEL THERAPY FOR MALIGNANT GLIOMA, filed on 12/1/2022. Official patent filing is currently in process, as of the time of manuscript submission. TJP, BSCE and BMK declare no potential conflicts of interest. LML is a board member and stock holder of ClearPoint Neuro, on the medical advisory board of InSightec, a paid consultant for ImmPact Bio, and has received research funding through UCLA from Northwest Biotherapeutics. PLN has contracts with UCLA for the Brain Tumor Program with BMS, Chimerix, Erasca, Springsworks, and Recursion. TFC is cofounder, major stock holder, consultant and board member of Katmai Pharmaceuticals, member of the board and paid consultant for the 501c3 Global Coalition for Adaptive Research, holds stock in Chimerix and receives milestone payments and possible future royalties, member of the scientific advisory board for Break Through Cancer, member of the scientific advisory board for Cure Brain Cancer Foundation, has provided paid consulting services to Sagimet, Clinical Care Options, Ideology Health, Servier, Jubilant, Immvira, Gan & Lee, BrainStorm, Katmai, Sapience, Inovio, Vigeo Therapeutics, DNATrix, Tyme, SDP, Novartis, Roche, Kintara, Bayer, Merck, Boehinger Ingelheim, VBL, Amgen, Kiyatec, Odonate Therapeutics QED, Medefield, Pascal Biosciences, Bayer, Tocagen, Karyopharm, GW Pharma, Abbvie, VBI, Deciphera, VBL, Agios, Genocea, Celgene, Puma, Lilly, BMS, Cortice, Wellcome Trust, Novocure, Novogen, Boston Biomedical, Sunovion, Human Longevity, Insys, ProNai, Pfizer, Notable labs, Medqia Trizel, Medscape and has contracts with UCLA for the Brain Tumor Program with Oncovir, Merck, Oncoceutics, Novartis, Amgen, Abbvie, DNAtrix, Beigene, BMS, AstraZeneca, Kazia, Agios, Boston Biomedical, Deciphera, Tocagen, Orbus, AstraZeneca, Karyopharm. The Regents of the University of California (TFC employer) has licensed intellectual property co-invented by TFC to Katmai Pharmaceuticals.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zapanta Rinonos, S., Li, T., Pianka, S.T. et al. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma. J Neurooncol 166, 129–142 (2024). https://doi.org/10.1007/s11060-023-04531-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-023-04531-z